Drug Profile
Research programme: synthetic Fc-alpha-1 antitrypsin - Omni Bio Pharmaceutical
Alternative Names: Fc fusion recombinant AAT; Fc-AAT; Fc-AAT 2; Fc-AAT 3; Recombinant-Fc-AAT; Synthetic- Fc-alpha-1 antitrypsin; Synthetic-Fc-AATLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Colorado at Denver
- Developer Omni Bio Pharmaceutical; University of Colorado at Denver
- Class Acute-phase proteins; Alpha globulins; Blood proteins; Recombinant fusion proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Serine protease inhibitors; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gouty arthritis; Graft-versus-host disease; Myocardial infarction; Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gouty arthritis in Netherlands (SC)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA (SC)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (SC)